Literature DB >> 22815535

Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys.

Cindy Achat-Mendes1, Donna M Platt, Roger D Spealman.   

Abstract

Within the group I family of metabotropic glutamate receptors (mGluRs), substantial evidence points to a role for mGluR5 mechanisms in cocaine's abuse-related behavioral effects, but less is understood about the contribution of mGluR1, which also belongs to the group I mGluR family. The selective mGluR1 antagonist JNJ16259685 [(3,4-dihydro-2H-pyrano-[2,3-b]quinolin-7-yl)-(cis-4-methoxycyclohexyl)-methanone] was used to investigate the role of mGluR1 in the behavioral effects of cocaine and methamphetamine. In drug discrimination experiments, squirrel monkeys were trained to discriminate cocaine from saline by using a two-lever, food-reinforced operant procedure. JNJ16259685 (0.56 mg/kg) pretreatments significantly attenuated cocaine's discriminative stimulus effects and the cocaine-like discriminative stimulus effects of methamphetamine. In monkeys trained to self-administer cocaine or methamphetamine under a second-order schedule of intravenous drug injection, JNJ16259685 (0.56 mg/kg) significantly reduced drug-reinforced responding, resulting in a downward displacement of dose-response functions. In reinstatement studies, intravenous priming with cocaine accompanied by restoration of a cocaine-paired stimulus reinstated extinguished cocaine-seeking behavior, which was significantly attenuated by JNJ16259685 (0.56 mg/kg). Finally, in experiments involving food rather than drug self-administration, cocaine and methamphetamine increased the rate of responding, and the rate-increasing effects of both psychostimulants were significantly attenuated by JNJ16259685 (0.3 mg/kg). At the doses tested, JNJ16259685 did not significantly suppress food-reinforced behavior (drug discrimination or fixed-interval schedule of food delivery), but did significantly reduce species-typical locomotor activity in observational studies. To the extent that the psychostimulant-antagonist effects of JNJ16259685 are independent of motor function suppression, further research is warranted to investigate other mGluR1 antagonists for potential therapeutic value in psychostimulant abuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815535      PMCID: PMC3464036          DOI: 10.1124/jpet.112.196295

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

Review 1.  Pharmacological and environmental determinants of relapse to cocaine-seeking behavior.

Authors:  R D Spealman; R L Barrett-Larimore; J K Rowlett; D M Platt; T V Khroyan
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

2.  Dissociation of cocaine-antagonist properties and motoric effects of the D1 receptor partial agonists SKF 83959 and SKF 77434.

Authors:  D M Platt; J K Rowlett; R D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2000-06       Impact factor: 4.030

Review 3.  Glutamatergic mechanisms in addiction.

Authors:  T M Tzschentke; W J Schmidt
Journal:  Mol Psychiatry       Date:  2003-04       Impact factor: 15.992

4.  JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist.

Authors:  Hilde Lavreysen; Ria Wouters; François Bischoff; Sandrina Nóbrega Pereira; Xavier Langlois; Saskia Blokland; Marijke Somers; Lieve Dillen; Anne S J Lesage
Journal:  Neuropharmacology       Date:  2004-12       Impact factor: 5.250

5.  Group I mGlu receptor modulation of dopamine release in the rat striatum in vivo.

Authors:  R K Bruton; J Ge; N M Barnes
Journal:  Eur J Pharmacol       Date:  1999-03-19       Impact factor: 4.432

6.  Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM.

Authors:  Tomoteru Yamasaki; Masayuki Fujinaga; Jun Maeda; Kazunori Kawamura; Joji Yui; Akiko Hatori; Yuichiro Yoshida; Yuji Nagai; Masaki Tokunaga; Makoto Higuchi; Tetsuya Suhara; Toshimitsu Fukumura; Ming-Rong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-24       Impact factor: 9.236

7.  Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer.

Authors:  C J Swanson; D A Baker; D Carson; P F Worley; P W Kalivas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

8.  Evidence for perceptual masking of the discriminative morphine stimulus.

Authors:  D V Gauvin; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes.

Authors:  R D Spealman; J Bergman; B K Madras; K F Melia
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

Review 10.  The ups and downs of addiction: role of metabotropic glutamate receptors.

Authors:  Paul J Kenny; Athina Markou
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

View more
  22 in total

1.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

2.  Group I metabotropic glutamate receptor-mediated activation of PKC gamma in the nucleus accumbens core promotes the reinstatement of cocaine seeking.

Authors:  Heath D Schmidt; Blake A Kimmey; Adrian C Arreola; R Christopher Pierce
Journal:  Addict Biol       Date:  2014-02-09       Impact factor: 4.280

3.  Modulatory effects of Ampicillin/Sulbactam on glial glutamate transporters and metabotropic glutamate receptor 1 as well as reinstatement to cocaine-seeking behavior.

Authors:  Alaa M Hammad; Fawaz Alasmari; Yusuf S Althobaiti; Youssef Sari
Journal:  Behav Brain Res       Date:  2017-06-15       Impact factor: 3.332

Review 4.  mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

Authors:  Olga A Dravolina; Edwin Zvartau; Wojciech Danysz; Anton Y Bespalov
Journal:  Psychopharmacology (Berl)       Date:  2017-03-11       Impact factor: 4.530

5.  N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.

Authors:  Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Daryl F Venable; Anna L Blobaum; Frank W Byers; J Scott Daniels; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte
Journal:  Bioorg Med Chem Lett       Date:  2016-03-09       Impact factor: 2.823

6.  Agmatine attenuates the discriminative stimulus and hyperthermic effects of methamphetamine in male rats.

Authors:  David A Thorn; Jiuzhou Li; Yanyan Qiu; Jun-Xu Li
Journal:  Behav Pharmacol       Date:  2016-09       Impact factor: 2.293

Review 7.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

8.  Metabotropic glutamate receptor I (mGluR1) antagonism impairs cocaine-induced conditioned place preference via inhibition of protein synthesis.

Authors:  Fei Yu; Peng Zhong; Xiaojie Liu; Dalong Sun; Hai-Qing Gao; Qing-Song Liu
Journal:  Neuropsychopharmacology       Date:  2013-01-24       Impact factor: 7.853

Review 9.  The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis.

Authors:  M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Neuroimmune basis of methamphetamine toxicity.

Authors:  Jennifer M Loftis; Aaron Janowsky
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.